EAM
TGTX icon

EverPoint Asset Management’s TG Therapeutics TGTX Stock Holding History

EverPoint Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-154,689
Closed -$2.45M – 592
2014
Q4 		$2.45M Buy
+154,689
New +$2.01M 0.06% 347

Other funds holding TGTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

EverPoint Asset Management's TGTX Position: Q1 2015 in Review

EverPoint Asset Management sold out of TG Therapeutics (TGTX) in Q1 2015, closing a stake of 154,689 shares — an estimated $2.45M sold.

EverPoint Asset Management first reported a position in TGTX in Q4 2014 and held it in 1 quarter. The position peaked at $2.45M in Q4 2014. 79 funds tracked by Wall St. Rank hold TGTX as of Q1 2015.

  • EverPoint Asset Management reported no remaining TG Therapeutics position as of Q1 2015 after selling out during the quarter.
  • EverPoint Asset Management sold 154,689 TG Therapeutics shares in Q1 2015, an estimated $2.45M.
  • EverPoint Asset Management first reported a position in TG Therapeutics in Q4 2014 and held it in 1 quarter.
  • EverPoint Asset Management's TG Therapeutics position peaked at $2.45M in Q4 2014.
  • 79 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2015.

Based on EverPoint Asset Management's 13F filing for Q1 2015, filed 15 May 2015.